Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
AIDS-Related Opportunistic Infections
/ microbiology
Adolescent
Adult
Antibiotic Prophylaxis
Antitubercular Agents
/ therapeutic use
Cross-Sectional Studies
Female
HIV Infections
/ complications
Humans
Isoniazid
/ therapeutic use
Latent Tuberculosis
/ drug therapy
Male
Middle Aged
Multilevel Analysis
Tanzania
/ epidemiology
Tuberculosis
/ epidemiology
Young Adult
HIV
IPT completion
Predictors
Tanzania
Tuberculosis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
10 Apr 2020
10 Apr 2020
Historique:
received:
10
12
2019
accepted:
27
03
2020
entrez:
12
4
2020
pubmed:
12
4
2020
medline:
9
7
2020
Statut:
epublish
Résumé
Tuberculosis (TB) disease is a common opportunistic infection among people living with HIV (PLHIV). WHO recommends at least 6 months of isoniazid Preventive Therapy (IPT) to reduce the risk of active TB. It is important to monitor the six-month IPT completion since a suboptimal dose may not protect PLHIV from TB infection. This study determined the six-month IPT completion and factors associated with six-month IPT completion among PLHIV aged 15 years or more in Dar es Salaam region, Tanzania. Secondary analysis of routine data from PLHIV attending 58 care and treatment clinics in Dar es Salaam region was used. PLHIV, aged 15 years and above, who screened negative for TB symptoms and initiated IPT from January, 2013 to June, 2017 were recruited. Modified Poisson regression with robust standard errors was used to estimate prevalence ratios (PR) and 95% confidence interval (CI) for factors associated with IPT completion. Multilevel analysis was used to account for health facility random effects in order to estimate adjusted PR (APR) for factors associated with IPT six-month completion. A total of 29,382 PLHIV were initiated IPT, with 21,808 (74%) female. Overall 17,092 (58%) six-month IPT completion, increasing from 42% (773/1857) in year 2013 to 76% (2929/3856) in 2017. Multilevel multivariable model accounting for health facilities as clusters, showed PLHIV who were not on ART had 46% lower IPT completion compared to those were on ART (APR: 0.54: 95%CI: 0.45-0.64). There was 37% lower IPT completion among PLHIV who transferred from another clinic (APR: 0.63: 95% CI (0.54-0.74) compared to those who did not transfer. PLHIV aged 25-34 years had a 6% lower prevalence of IPT completion as compared to those aged 15 to 24 years (APR:0.94 95%CI:0.89-0.98). The IPT completion rate in PLHIV increased over time, but there was lower IPT completion in PLHIV who transferred from other clinics, who were aged 25 to 34 years and those not on ART. Interventions to support IPT in these groups are urgently needed.
Sections du résumé
BACKGROUND
BACKGROUND
Tuberculosis (TB) disease is a common opportunistic infection among people living with HIV (PLHIV). WHO recommends at least 6 months of isoniazid Preventive Therapy (IPT) to reduce the risk of active TB. It is important to monitor the six-month IPT completion since a suboptimal dose may not protect PLHIV from TB infection. This study determined the six-month IPT completion and factors associated with six-month IPT completion among PLHIV aged 15 years or more in Dar es Salaam region, Tanzania.
METHODS
METHODS
Secondary analysis of routine data from PLHIV attending 58 care and treatment clinics in Dar es Salaam region was used. PLHIV, aged 15 years and above, who screened negative for TB symptoms and initiated IPT from January, 2013 to June, 2017 were recruited. Modified Poisson regression with robust standard errors was used to estimate prevalence ratios (PR) and 95% confidence interval (CI) for factors associated with IPT completion. Multilevel analysis was used to account for health facility random effects in order to estimate adjusted PR (APR) for factors associated with IPT six-month completion.
RESULTS
RESULTS
A total of 29,382 PLHIV were initiated IPT, with 21,808 (74%) female. Overall 17,092 (58%) six-month IPT completion, increasing from 42% (773/1857) in year 2013 to 76% (2929/3856) in 2017. Multilevel multivariable model accounting for health facilities as clusters, showed PLHIV who were not on ART had 46% lower IPT completion compared to those were on ART (APR: 0.54: 95%CI: 0.45-0.64). There was 37% lower IPT completion among PLHIV who transferred from another clinic (APR: 0.63: 95% CI (0.54-0.74) compared to those who did not transfer. PLHIV aged 25-34 years had a 6% lower prevalence of IPT completion as compared to those aged 15 to 24 years (APR:0.94 95%CI:0.89-0.98).
CONCLUSION
CONCLUSIONS
The IPT completion rate in PLHIV increased over time, but there was lower IPT completion in PLHIV who transferred from other clinics, who were aged 25 to 34 years and those not on ART. Interventions to support IPT in these groups are urgently needed.
Identifiants
pubmed: 32276618
doi: 10.1186/s12879-020-04997-6
pii: 10.1186/s12879-020-04997-6
pmc: PMC7147031
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
276Subventions
Organisme : This work was supported through the DELTAS Africa Initiative Grant No. 107754/Z/15/Z-DELTAS Africa SSACAB. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Scie
ID : 107754/Z/15/Z
Références
Infect Dis Poverty. 2017 Mar 24;6(1):64
pubmed: 28335816
BMC Infect Dis. 2015 Aug 26;15:368
pubmed: 26306511
BMC Infect Dis. 2015 Aug 13;15:334
pubmed: 26269094
AIDS. 2010 Nov;24 Suppl 5:S49-56
pubmed: 21079428
Can J Infect Dis Med Microbiol. 2018 Jul 4;2018:1346104
pubmed: 30073038
Int J Tuberc Lung Dis. 2008 Sep;12(9):1037-41
pubmed: 18713501
J Antimicrob Chemother. 2017 Mar 1;72(3):876-881
pubmed: 27999054
Patient Prefer Adherence. 2017 Apr 10;11:743-749
pubmed: 28435232
Front Public Health. 2020 Feb 06;7:404
pubmed: 32117844
East Afr Med J. 2000 Sep;77(9):494-7
pubmed: 12862141
Int J Tuberc Lung Dis. 2017 May 01;21(5):537-543
pubmed: 28399969
Clin Infect Dis. 2010 May 15;50 Suppl 3:S215-22
pubmed: 20397951
Lancet Infect Dis. 2016 Nov;16(11):1269-1278
pubmed: 27522233
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):273-279
pubmed: 29471904
PLoS One. 2012;7(12):e52489
pubmed: 23285064
AIDS. 2015 Jan 28;29(3):351-9
pubmed: 25686683
Lancet Respir Med. 2018 Apr;6(4):299-314
pubmed: 29595511
Public Health Action. 2017 Mar 21;7(1):55-60
pubmed: 28775944
BMJ Open. 2019 May 29;9(5):e029058
pubmed: 31147370
BMC Infect Dis. 2019 Jan 17;19(1):62
pubmed: 30654753
Public Health Action. 2018 Mar 21;8(1):20-24
pubmed: 29581939
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):e115-e117
pubmed: 28885271
AIDS. 2015 Sep 24;29(15):2055-7
pubmed: 26352882
Int J Tuberc Lung Dis. 2012 Jul;16(7):871-9
pubmed: 22410101
Patient Relat Outcome Meas. 2010 Jul;1:81-91
pubmed: 22915955
Int J Tuberc Lung Dis. 2011 Nov;15(11):1515-21, i
pubmed: 22008766
Int J Environ Res Public Health. 2017 Oct 07;14(10):
pubmed: 28991169
PLoS One. 2016 May 19;11(5):e0155525
pubmed: 27196627
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):74-81
pubmed: 28797022